John Paul DeJoria - 09 Sep 2025 SCHEDULE 13G Report for Telomir Pharmaceuticals, Inc. Common Stock, no par value (TELO)

Filing Manager: John Paul DeJoria
Reporting Manager: John Paul DeJoria, as trustee of the John Paul DeJoria Family Trust, and in his individual capacity
Security: Telomir Pharmaceuticals, Inc. Common Stock, no par value
Symbol: TELO
Shares outstanding: 32,270,909 shares
Disclosed Ownership: 1,774,900 shares
Ownership: 5.5%
Form type: SCHEDULE 13G
Filing time: 18 Sep 2025, 18:48:08 UTC
Date of event: 09 Sep 2025
Next filing: 12 Feb 2026
SEC: View on sec.gov

Quoteable Key Fact

"John Paul DeJoria disclosed 5.5% ownership in Telomir Pharmaceuticals, Inc. Common Stock, no par value (TELO) on 09 Sep 2025."

Quick Takeaways

John Paul DeJoria filed SCHEDULE 13G for Telomir Pharmaceuticals, Inc. Common Stock, no par value (TELO).
Disclosed ownership: 5.5%.
Date of event: 09 Sep 2025.

This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
You can verify ownership claims directly against the original SEC filing.

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

Name	Ownership	Shares Owned	sole voting power	shared voting power	Signature	Title	CIK
John Paul DeJoria, as trustee of the John Paul DeJoria Family Trust, and in his individual capacity	5.5%	1,774,900	1,774,900	0	/s/ Matthew R. Bair	Matthew R. Bair, Attorney-in-Fact